Stimuli-responsive liposome development: The ultimate goal of drug delivery is to increase the bioavailability and reduce its side effects by releasing active pharmaceutical ingredient (API) at specific sites of action. In the case of anti-tumor therapy, the combination of therapeutic agent and carrier system can minimize the damage to healthy non target tissues. At the same time, due to enhanced permeability and retention (EPR), it can limit systemic release and promote long circulation to enhance uptake of cancer site.